Tags

Type your tag names separated by a space and hit enter

In vitro and in vivo activities of the novel Ketolide RBx 14255 against Clostridium difficile.
Antimicrob Agents Chemother. 2012 Nov; 56(11):5986-9.AA

Abstract

The MIC(90) of RBx 14255, a novel ketolide, against Clostridium difficile was 4 μg/ml (MIC range, 0.125 to 8 μg/ml), and this drug was found to be more potent than comparator drugs. An in vitro time-kill kinetics study of RBx 14255 showed time-dependent bacterial killing for C. difficile. Furthermore, in the hamster model of C. difficile infection, RBx 14255 demonstrated greater efficacy than metronidazole and vancomycin, making it a promising candidate for C. difficile treatment.

Authors+Show Affiliations

Department of Infectious Diseases, New Drug Discovery Research, Ranbaxy Research Laboratories, Gurgaon, India.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22869573

Citation

Kumar, Manoj, et al. "In Vitro and in Vivo Activities of the Novel Ketolide RBx 14255 Against Clostridium Difficile." Antimicrobial Agents and Chemotherapy, vol. 56, no. 11, 2012, pp. 5986-9.
Kumar M, Mathur T, Barman TK, et al. In vitro and in vivo activities of the novel Ketolide RBx 14255 against Clostridium difficile. Antimicrob Agents Chemother. 2012;56(11):5986-9.
Kumar, M., Mathur, T., Barman, T. K., Ramkumar, G., Bhati, A., Shukla, G., Kalia, V., Pandya, M., Raj, V. S., Upadhyay, D. J., Vaishnavi, C., Chakrabarti, A., Das, B., & Bhatnagar, P. K. (2012). In vitro and in vivo activities of the novel Ketolide RBx 14255 against Clostridium difficile. Antimicrobial Agents and Chemotherapy, 56(11), 5986-9. https://doi.org/10.1128/AAC.00015-12
Kumar M, et al. In Vitro and in Vivo Activities of the Novel Ketolide RBx 14255 Against Clostridium Difficile. Antimicrob Agents Chemother. 2012;56(11):5986-9. PubMed PMID: 22869573.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - In vitro and in vivo activities of the novel Ketolide RBx 14255 against Clostridium difficile. AU - Kumar,Manoj, AU - Mathur,Tarun, AU - Barman,Tarani K, AU - Ramkumar,G, AU - Bhati,Ashish, AU - Shukla,Gunjan, AU - Kalia,Vandana, AU - Pandya,Manisha, AU - Raj,V Samuel, AU - Upadhyay,Dilip J, AU - Vaishnavi,Chetana, AU - Chakrabarti,Anjan, AU - Das,Biswajit, AU - Bhatnagar,Pradip K, Y1 - 2012/08/06/ PY - 2012/8/8/entrez PY - 2012/8/8/pubmed PY - 2013/4/24/medline SP - 5986 EP - 9 JF - Antimicrobial agents and chemotherapy JO - Antimicrob Agents Chemother VL - 56 IS - 11 N2 - The MIC(90) of RBx 14255, a novel ketolide, against Clostridium difficile was 4 μg/ml (MIC range, 0.125 to 8 μg/ml), and this drug was found to be more potent than comparator drugs. An in vitro time-kill kinetics study of RBx 14255 showed time-dependent bacterial killing for C. difficile. Furthermore, in the hamster model of C. difficile infection, RBx 14255 demonstrated greater efficacy than metronidazole and vancomycin, making it a promising candidate for C. difficile treatment. SN - 1098-6596 UR - https://www.unboundmedicine.com/medline/citation/22869573/In_vitro_and_in_vivo_activities_of_the_novel_Ketolide_RBx_14255_against_Clostridium_difficile_ L2 - http://aac.asm.org/cgi/pmidlookup?view=long&pmid=22869573 DB - PRIME DP - Unbound Medicine ER -